Non-malignant hematologic disorders 1, congenital and acquired aplastic anemia: especially the presence of life-threatening irreversible bone marrow failure or remittent disease that is ineffective to immunosuppressive therapy. 2. hereditary red blood cell disease, 3. hereditary immunodeficiency, 4. hereditary metabolic disease. Xiaowei Hu, Department of Hematology, The First Hospital of Soochow University NMDP recommended indications for URD-HSCT in malignant hematologic diseases and timing of transplantation are as follows: 1, Acute Myeloid Leukemia (AML) ① High-risk AML: secondary AML (e.g., previous history of MDS), treatment-related leukemia, failure of induction therapy; ② CR1 in patients with high cytogenetic risk; ③ CR2 or CR3. 2, Acute Lymphoblastic Leukemia (AML) 2. acute lymphoblastic leukemia (ALL) ① high risk ALL; ② cytogenetic high risk patients (e.g. Ph chromosome positive, 11q23); ③ high white (>30 C 50×109/L) at initial diagnosis; ④ central nervous system leukemia or testicular leukemia; ⑤ no CR at 4 weeks of initial induction therapy; ⑥ induction therapy failure; ⑦ CR2 or CR3. 3. myelodysplastic syndrome ( MDS) IPSS intermediate-risk-1 (INT-1), intermediate-risk-2 (INT-2) or IPSS high score and include any of the following: ① bone marrow primitive cells > 5% ② except for patients with good cytogenetic prognosis [including 5q- obtained normal karyotype] ③ > 1 lineage cytopenia. 4. Sexual myeloid leukemia (CML) ① No hematologic or secondary cytogenetic response 3 months after imatinib treatment, ② No complete cytogenetic response 6 to 12 months after imatinib treatment, ③ Disease progression (accelerated or acute phase). 5.Lymphoma